FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
This article was originally published in The Pink Sheet Daily
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.
You may also be interested in...
Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.
Interleukin-6 inhibitor is first biologic to show superiority in reducing signs and symptoms.
FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.